All articles tagged with #ssris
Health Secretary RFK Jr. is advancing a deprescribing initiative to reduce antidepressant use. Federal officials and mental health professionals gathered to draft forthcoming clinical guidance on tapering SSRIs and expanding nonmedication options like therapy, while highlighting gaps in research on withdrawal symptoms and relapse versus recurrence of depressive symptoms.
New multicenter data link reduced serotonin transporter (SERT) activity and SSRI use with faster progression of degenerative mitral regurgitation (DMR); animal models show serotonin-related valve thickening, and a 5-HTTLPR long-long genetic variant appears to heighten risk by increasing valve cell response to serotonin and collagen buildup. Findings suggest potential for genetic risk testing to identify patients who may need earlier surgery and point to new therapeutic targets (e.g., HTR2B), while SSRIs remain generally safe for most people.
America’s use of anxiety medications jumped from 11.7% of adults in 2019 to 14.3% in 2024—roughly 38 million people—driven by easier telehealth access and pandemic-related stress. SSRIs like Lexapro, Prozac, and Zoloft are frontline treatments for disorders such as generalized anxiety and panic, with studies showing meaningful relief for many despite side effects; experts caution that they are most effective when paired with therapy, and note benzodiazepines carry dependence risks. Public figures, including RFK Jr., have questioned expanding SSRI use and potential links to behavior or pregnancy outcomes, fueling a broader debate about medicalization, safety, and access. The rise is greatest among young adults, women, and those with higher education or LGBTQ+ identification, while talk therapy and broader mental-health support also grew during this period.
Health and Human Services Secretary Robert F. Kennedy Jr. appointed two obstetrician-gynecologists, Dr. Adam Urato and Dr. Kimberly Biss, to the CDC’s Advisory Committee on Immunization Practices, despite their histories of challenging vaccine safety consensus and questioning antidepressants in pregnancy. The hires come as Kennedy reshapes ACIP amid concerns about conflicts of interest and amid ongoing debate within the panel over Covid vaccine recommendations and broader immunization policy.
The article discusses the lack of research on how SSRIs, commonly prescribed antidepressants, affect the sexual development of teenagers, highlighting concerns about potential long-term sexual side effects in young people.
A comprehensive study analyzing over 150 clinical trials found that newer antidepressants like SSRIs generally have fewer physical side effects compared to older medications, providing valuable data to help personalize treatment choices, though individual responses may vary.
A doctor shares his personal experience and discusses the complexities of stopping antidepressants, particularly SSRIs, highlighting the need for personalized tapering methods and better understanding of withdrawal symptoms to improve mental health treatment.
Many people find stopping SSRIs difficult, experiencing prolonged and severe withdrawal symptoms, but researchers are still unsure why due to a lack of comprehensive studies and clear definitions, prompting calls for more research into the long-term effects of discontinuing antidepressants.
The article criticizes an FDA panel for exaggerating the risks of antidepressant use during pregnancy, highlighting the importance of maternal mental health and the author's personal experience of safely continuing medication during pregnancy, arguing that such misinformation could hinder women’s access to necessary treatment.
Robert F. Kennedy Jr. and Vice President JD Vance have promoted unfounded theories linking SSRIs and psychiatric medications to violence and school shootings, despite scientific evidence disproving such connections, amid ongoing mass shootings in the U.S.
An FDA advisory panel has recommended warning labels for antidepressants during pregnancy due to potential risks like autism, miscarriage, and birth defects, though the medical consensus generally considers these medications safe and emphasizes the dangers of untreated depression. Experts highlight that most SSRIs are safe for pregnant women, with some risks like neonatal adaptation syndrome, and warn against unnecessary discontinuation of medication, which could harm both mother and child. Critics argue the panel's warnings may cause undue fear and discourage necessary treatment.
The author shares their personal journey of tapering off SSRIs after nearly a decade, reflecting on the emotional and physical challenges faced, the societal debates surrounding antidepressant use, and the importance of nuanced understanding and professional guidance in mental health treatment.
An FDA panel discussion on antidepressant use during pregnancy highlighted skepticism about the safety of SSRIs, despite evidence suggesting that untreated mental health issues pose significant risks to pregnant individuals. Critics argue the panel's focus was biased, emphasizing risks over benefits, which may influence pregnant people's treatment decisions and overlook the importance of managing mental health during pregnancy.
An FDA panel's discussion on antidepressants during pregnancy was criticized by psychiatrists for spreading misinformation and lacking balance, with some panelists emphasizing unproven risks and questioning drug efficacy, despite medical consensus supporting the safety and importance of SSRIs for pregnant women with depression.
Bella Mackie shares her personal experience with long-term use of antidepressants, the challenges of tapering off SSRIs, and the lack of adequate information and support from healthcare providers about withdrawal symptoms, highlighting the need for better guidance and awareness.